Groundbreaking Studies Find That Neurointerventional Surgery Reduces Stroke Mortality

WASHINGTON, Feb. 11, 2015 /PRNewswire/ -- Two new clinical trials on the treatment of stroke (ESCAPE and EXTEND IA) demonstrate that neurointerventional surgery significantly increases the number of patients who are able to live independently without major neurological disabilities. The ESCAPE study, published today in the New England Journal of Medicine, also shows that neurointerventional surgery reduces stroke mortality by 50 percent.

ESCAPE (Endovascular treatment for Small Core and Anterior circulation Proximal occasion with Emphasis on minimizing CT to recanalization times) and EXTEND IA (Extending the Time for Thrombolysis in Emergency Neurological Deficits - Intra-Arterial) are two of three studies (together with SWIFT PRIME) that confirm the MR CLEAN study published in the New England Journal of Medicine late last year--which showed that the addition of inside-the-artery clot removal is more effective than IV-administered "clot-busting" tissue plasminogen activator (IV-tPA) treatment alone for the treatment of stroke.

"All three of these studies confirm what we are seeing in everyday practice. In many cases, instead of suffering major neurological disability, patients are able to go home to resume their lives," said Dr. Peter Rasmussen, director of the Cerebrovascular Center, Cleveland Clinic in Cleveland, Ohio, and president of the Society of NeuroInterventional Surgery (SNIS). "Within-the-artery procedures, which are performed by neurointerventional surgeons, are not the appropriate treatment for every patient suffering from stroke, but for those patients experiencing the most severe types of ischemic strokes, they are life-saving, viable and effective therapies that offer many benefits over traditional treatments, including shorter recovery times and a better chance to return to normal activities."

ESCAPE is the first study to show that the overall stroke mortality rate was reduced by 50 percent with neurointerventional surgery, from two in 10 patients for standard-of-care treatment to one in 10. ESCAPE and EXTEND IA showed better outcomes for those patients treated with neurointerventional surgery. In ESCAPE, nearly 30 percent of patients treated with IV-tPA treatment alone were able to live independently without major neurological disabilities. For patients receiving neurointerventional surgery, that number increased to 53 percent. EXTEND IA showed even better results, with 71 percent of patients who received neurointerventional surgery returning to independent living, compared with 40 percent in the standard treatment group.

According to Dr. Peter Mitchell, co-principal investigator of EXTEND IA and the director of neurointervention at the Royal Melbourne Hospital, two of the key differences in better outcomes for stroke patients were the use of more advanced brain imaging to select patients most likely to benefit and earlier treatment. The Royal Melbourne Hospital, where the EXTEND IA study was conducted, treats approximately 500 ischemic stroke patients a year and is one of the few stroke centers in the world to treat patients within 20 minutes of arriving in the emergency department.

According to Dr. Donald Frei, a neurointerventional surgeon at Radiology Imaging Associates in Denver, Colo., and president-elect of SNIS, treatment time is critical. While ESCAPE showed that neurointerventional surgery can be performed up to 12 hours from the onset of stroke, the success of the trial can be credited to fast treatment and the use of brain and blood vessel imaging. In ESCAPE, researchers were on average two hours faster in opening the blocked blood vessels than in previously reported trials.

"These positive studies are important milestones in the transformation of care for stroke patients, but it's also important to understand that the comprehensive stroke centers that participated excel in providing this type care," said Dr. Frei. "The results may not be replicable in every hospital. It's important that when stroke occurs, the disease is identified quickly and patients are transported to facilities that are equipped to provide the best evidence-based interventions for ischemic and hemorrhagic stroke management."

ESCAPE included 22 sites worldwide and patients in the U.S., U.K., Ireland and South Korea and evaluated the effect of endovascular treatment for patients with acute ischemic stroke caused by a clot obstructing one of the major intracranial arteries. The study was ended early because it crossed the pre-specified boundary for efficacy. The study included 316 patients who fit the criteria for neurointerventional surgery and arrived for treatment within 12 hours of their stroke who were randomized to standard medical care (which included the IV-tPA where appropriate) or standard medical care plus neurointerventional surgery. 

The EXTEND IA trial compared IV-tPA to IV-tPA and neurointerventional surgery in patients with acute ischemic stroke receiving IV therapy within 4.5 hours of stroke onset. Patients were selected using CTA and CTP to identify those with large vessel occlusion and small core infarct with significant volume of "threatened" tissue. The trial was stopped early because of efficacy when 70 of the intended 100 patients had been randomized (35 to each arm) after the presentation of the MR CLEAN results prompted the DSMB to perform a pre-specified analysis.

Of 695,000 people who suffer acute ischemic stroke in the U.S., 40 percent have a large-vessel blockage, which often leads to death or permanent disability. These neurointerventional procedures have potential life-saving benefits for almost 300,000 people in the U.S. who suffer a stroke with a large vessel blockage. Stroke is the leading cause of disability and the fourth cause of death in U.S. In 2010, stroke cost the U.S. an estimated $54 billion, including the cost of health care services, medications and missed days of work. Strokes cost $74 billion in health care expenditures annually for treatment due to disability.

Neurointerventional surgery is a critical piece of a system of stroke care that has helped reduce death rates from stroke by more than 35 percent from 2000 to 2010. This includes public education to reduce risk factors and recognize the symptoms of stroke, emergency medical services processes and protocols to appropriately assess patients and emergency transport guidelines that immediately deliver stroke patients to a comprehensive stroke center. SNIS works to develop general standards to define principles of practice that will produce high-quality care and provides guidance on standardized techniques, procedures and practices in the neurointerventional field, not only to improve health care outcomes but also to define the core practice from which this specialty can build and grow.

About The Society of NeuroInterventional Surgery

The Society of NeuroInterventional Surgery (SNIS) is a scientific and educational association, made up of neurointerventional surgeons, dedicated to advancing the specialty of neurointerventional surgery through research, standard-setting and education and advocacy in order to provide the highest quality of patient care in diagnosing and treating diseases of the brain, spine, head and neck. 

Contact:
Andy Sousa
TogoRun
Phone: 202-828-5069
Email: [email protected]

SOURCE Society of NeuroInterventional Surgery